Literature DB >> 11557500

Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.

R S Malone1, D N Fish, E Abraham, I Teitelbaum.   

Abstract

The pharmacokinetics of intravenously administered levofloxacin and ciprofloxacin were studied in intensive care unit patients during continuous venovenous hemofiltration (CVVH; four patients received levofloxacin, and five received ciprofloxacin) or hemodiafiltration (CVVHDF; six patients received levofloxacin, and five received ciprofloxacin). Levofloxacin clearance was substantially increased during both CVVH and CVVHDF, while ciprofloxacin clearance was affected less. The results of this study suggest that doses of levofloxacin of 250 mg/day and ciprofloxacin of 400 mg/day are sufficient to maintain effective drug concentrations in the plasma of patients undergoing CVVH or CVVHDF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557500      PMCID: PMC90762          DOI: 10.1128/AAC.45.10.2949-2954.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Ciprofloxacin in renal failure.

Authors:  D E Roberts; J D Williams
Journal:  J Antimicrob Chemother       Date:  1989-06       Impact factor: 5.790

2.  Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.

Authors:  G L Drusano; M Weir; A Forrest; K Plaisance; T Emm; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 3.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

4.  Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.

Authors:  P D Lister; C C Sanders
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

5.  Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

Authors:  C A Peloquin; T J Cumbo; D E Nix; M F Sands; J J Schentag
Journal:  Arch Intern Med       Date:  1989-10

6.  Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.

Authors:  E Singlas; A M Taburet; I Landru; H Albin; J P Ryckelinck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis.

Authors:  S P Davies; B S Azadian; W J Kox; E A Brown
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

8.  The pharmacokinetics of ciprofloxacin in patients with impaired renal function.

Authors:  J Boelaert; Y Valcke; M Schurgers; R Daneels; M Rosseneu; M T Rosseel; M G Bogaert
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

9.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

10.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

View more
  14 in total

1.  Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

Authors:  Sean K Gorman; Richard S Slavik; Stefanie Lam
Journal:  Can J Hosp Pharm       Date:  2012-05

Review 2.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

Authors:  Valentina Pistolesi; Santo Morabito; Francesca Di Mario; Giuseppe Regolisti; Chiara Cantarelli; Enrico Fiaccadori
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Authors:  Eugenia Yeh; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

5.  Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing.

Authors:  Catherine S C Bouman; Hendrikus J M van Kan; Richard P Koopmans; Johanna C Korevaar; Marcus J Schultz; Margreeth B Vroom
Journal:  Intensive Care Med       Date:  2006-10-17       Impact factor: 17.440

Review 6.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

7.  Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.

Authors:  Douglas N Fish; Isaac Teitelbaum; Edward Abraham
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 8.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.

Authors:  Almath M Spooner; Catherine Deegan; Deirdre M D'Arcy; Caitriona M Gowing; Maria B Donnelly; Owen I Corrigan
Journal:  BMC Clin Pharmacol       Date:  2011-08-04

10.  Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy.

Authors:  Larry M Bush; Fredy Chaparro-Rojas; Victor Okeh; Joseph Etienne
Journal:  Infect Drug Resist       Date:  2011-10-18       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.